Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer
Publication in refereed journal

Times Cited
Web of Science10WOS source URL (as at 23/10/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractBackground and PurposePelitinib is a potent irreversible EGFR TK inhibitor currently in clinical trials for the treatment of lung cancer. Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance treatment outcome. In this study, we investigated the ability of the combination of pelitinib with other conventional anticancer drugs to specifically target cancer cells with up-regulated efflux transporters ABCB1/ABCG2 after hyperthermia as a novel way to eradicate the cancer stem-like cells responsible for cancer recurrence.
All Author(s) ListTo KKW, Poon DC, Wei YM, Wang F, Lin G, Fu LW
Journal nameBritish Journal of Pharmacology
Detailed descriptionTo ORKTS: Epub ahead of print
Br J Pharmacol 2015 May 18. doi: 10.1111/bph.13189
Volume Number172
Issue Number16
Pages4089 - 4106
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesPharmacology & Pharmacy

Last updated on 2020-24-10 at 02:41